FDA Moves Dissolvable Antibiotic Bone Filler to Class II
Published Date: 6/5/2026
Rule
Summary
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier FDA Path for Device Makers
The FDA has classified a resorbable calcium salt bone void filler with a single approved aminoglycoside antibacterial as Class II, effective June 5, 2026 (classification applicable May 17, 2022). That means the product can serve as a predicate device so other makers can use the less-burdensome 510(k) premarket notification pathway instead of automatic Class III premarket approval, which the FDA says will reduce regulatory burdens and help speed patient access.
More Patient Access to Bone Filler
You (patients) may get earlier access to a resorbable bone void filler intended to reduce recurrence of chronic osteomyelitis of long bones because FDA placed this product into Class II with special controls (order effective June 5, 2026; classification applicable May 17, 2022). The rule also lists required safety measures — such as clinical and animal testing, labeling about risks (including antimicrobial resistance and systemic adverse effects), and sterility and stability data — to provide reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-11307, Amendment of Class E Airspace; Springfield, KY
The FAA is updating the Class E airspace around Lebanon Springfield Airport in Springfield, KY, to match new flight procedures and correct the airport’s name and location info. This change helps pilots fly safely using instruments and kicks in on September 3, 2026. No extra costs for anyone—just smoother skies and clearer rules!
Next: 2026-11311, Special Local Regulation; Genesee River, Rochester, NY
On June 20, 2026, the Coast Guard will temporarily block off part of the Genesee River in Rochester, NY, for a thrilling Harborfest Water Ski Show. Boats and people can’t enter the area from 11:45 a.m. to 5:30 p.m. unless they get special permission. This keeps everyone safe during the high-speed water fun without costing anyone a dime!